{
  "question_stem": {
    "en": "A 48-year-old man comes to establish care after moving to a new state. He feels well and has no symptoms. The patient has a history of type 2 diabetes mellitus diagnosed 6 months ago; he was prescribed metformin by his previous physician but stopped taking it due to diarrhea. He was unable to follow up with the physician and has not taken any other medications. The patient exercises regularly and follows a low-carbohydrate diet. Laboratory results show a fasting blood glucose of 140 mg/dL and a hemoglobin A1c of 7.5%. The physician counsels the patient about adding canagliflozin to optimize glycemic control. Which of the following tests should be ordered prior to initiating this new medication?",
    "zh": "一名48岁的男性在搬到新州后前来就诊以建立医疗关系。他感觉良好，没有任何症状。患者有6个月前诊断为2型糖尿病的病史；他以前的医生给他开了二甲双胍，但由于腹泻而停用了。他无法随访医生，也没有服用任何其他药物。患者 নিয়মিত 锻炼并遵循低碳水化合物饮食。实验室结果显示空腹血糖为140 mg/dL，糖化血红蛋白A1c为7.5%。医生建议患者添加卡格列净以优化血糖控制。在开始这种新药之前，应该订购以下哪项检查？"
  },
  "question": {
    "en": "Which of the following tests should be ordered prior to initiating this new medication?",
    "zh": "在开始这种新药之前，应该订购以下哪项检查？"
  },
  "options": {
    "A": {
      "en": "Leukocyte count",
      "zh": "白细胞计数"
    },
    "B": {
      "en": "Serum creatinine",
      "zh": "血清肌酐"
    },
    "C": {
      "en": "Serum uric acid",
      "zh": "血清尿酸"
    },
    "D": {
      "en": "Thyroid function tests",
      "zh": "甲状腺功能检查"
    },
    "E": {
      "en": "Urinalysis",
      "zh": "尿液分析"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "Sodium-glucose cotransporter-2 (SGLT-2) is a low-affinity, high-capacity transport protein that reabsorbs 90% of filtered glucose in the proximal tubule. SGLT-2 inhibitors (eg, canagliflozin, dapagliflozin) are oral antidiabetic agents that decrease renal reabsorption of sodium and glucose and thereby decrease blood glucose levels. They are used primarily as a combination therapy (eg, with metformin), especially in patients with atherosclerotic cardiovascular disease (eg, prior myocardial infarction), heart failure, or nephropathy (eg, albuminuria).\n\nBecause SGLT-2 inhibitors rely on adequate renal glucose filtration to exert their antihyperglycemic effect, they become less effective or ineffective as renal function declines (eg, when estimated glomerular filtration rate [eGFR] falls <30-45 mL/min/1.73 m2). Therefore, checking serum creatinine (used to calculate eGFR) is recommended prior to medication initiation {{exhibit_1}}.\n\n(Choices A and E) Although SGLT-2 inhibitors increase the risk for genitourinary infections (eg, candidiasis, urinary tract infection), screening for infection with a leukocyte count and urinalysis in asymptomatic patients (eg, no dysuria or fever) is unnecessary.\n\n(Choice C) Certain drugs such as diuretics (eg, thiazide, loop) reduce renal uric acid clearance and may precipitate gout. However, SGLT-2 inhibitors are associated with increased renal uric acid clearance and are not expected to increase the risk for gout.\n\n(Choice D) Thyroid function tests are routinely performed on patients taking lithium and amiodarone, which can alter thyroid hormone metabolism. However, thyroid function tests are not required for antidiabetic medications.\n\nEducational objective:\nSodium-glucose cotransporter-2 inhibitors (eg, canagliflozin, dapagliflozin) lower glucose levels by decreasing renal reabsorption of glucose and have cardioprotective and renoprotective effects. Checking serum creatinine is recommended prior to initiation because the antihyperglycemic effect of these medications becomes less pronounced as renal function declines.",
    "zh": "钠-葡萄糖协同转运蛋白2 (SGLT-2) 是一种低亲和力、高容量的转运蛋白，可在近端小管中重吸收90%的滤过葡萄糖。SGLT-2抑制剂（例如，卡格列净、达格列净）是口服降糖药，可减少肾脏对钠和葡萄糖的重吸收，从而降低血糖水平。它们主要用作联合治疗（例如，与二甲双胍），尤其是在患有动脉粥样硬化性心血管疾病（例如，既往心肌梗死）、心力衰竭或肾病（例如，白蛋白尿）的患者中。\n\n由于SGLT-2抑制剂依赖于足够的肾脏葡萄糖滤过以发挥其降糖作用，因此随着肾功能的下降（例如，当估计肾小球滤过率[eGFR]降至<30-45 mL/min/1.73 m2时），它们的效果会降低或无效。因此，在开始用药之前，建议检查血清肌酐（用于计算eGFR）{{exhibit_1}}。\n\n（选项A和E）尽管SGLT-2抑制剂会增加泌尿生殖系统感染（例如，念珠菌病、尿路感染）的风险，但在无症状患者（例如，无排尿困难或发热）中，通过白细胞计数和尿液分析筛查感染是不必要的。\n\n（选项C）某些药物（如利尿剂（例如，噻嗪类、袢利尿剂））会降低肾脏尿酸清除率，并可能诱发痛风。然而，SGLT-2抑制剂与肾脏尿酸清除率增加有关，并且预计不会增加痛风的风险。\n\n（选项D）甲状腺功能检查通常在服用锂和胺碘酮的患者中进行，这两种药物可以改变甲状腺激素的代谢。但是，降糖药不需要进行甲状腺功能检查。\n\n教育目标：\n钠-葡萄糖协同转运蛋白2抑制剂（例如，卡格列净、达格列净）通过减少肾脏对葡萄糖的重吸收来降低血糖水平，并具有心脏保护和肾脏保护作用。建议在开始用药前检查血清肌酐，因为这些药物的降糖作用会随着肾功能的下降而变得不那么明显。"
  },
  "summary": {
    "en": "This question tests knowledge of SGLT-2 inhibitors and the importance of assessing renal function prior to initiation. SGLT-2 inhibitors rely on adequate renal glucose filtration to exert their antihyperglycemic effect. \n\nTo solve this question, recognize that SGLT-2 inhibitors' efficacy is dependent on renal function. Therefore, assessing renal function with a serum creatinine level is the most appropriate step before starting the medication.",
    "zh": "这个问题考察了对SGLT-2抑制剂的了解以及在开始用药前评估肾功能的重要性。SGLT-2抑制剂依赖于足够的肾脏葡萄糖滤过以发挥其降糖作用。\n\n要解决这个问题，需要认识到SGLT-2抑制剂的疗效取决于肾功能。因此，使用血清肌酐水平评估肾功能是在开始用药之前最合适的步骤。"
  },
  "tags": "Type 2 diabetes mellitus; SGLT-2 inhibitors; Canagliflozin; Renal function; Serum creatinine; Antihyperglycemic agents; Endocrinology; Nephrology",
  "category": "Endo",
  "question_id": "604",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Endo 23\\604",
  "extracted_at": "2025-11-05T14:08:45.075119",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:41:55.469612",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}